ArticleJournal of pharmacy & bioallied sciences2025
Evaluating the Role of Genetic Markers in Predicting Oral Leukoplakia Malignancy Transformation.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral leukoplakia is a common premalignant lesion in the oral cavity, with varying risks of transformation into oral squamous cell carcinoma (OSCC). Identifying reliable genetic markers to predict malignant transformation is crucial for early intervention and improved patient outcomes. Materials and Methods: A prospective cohort study was conducted on 150 patients diagnosed with oral leukoplakia. Tissue samples were collected from all patients and analyzed for genetic markers, including p53, cyclin D1, and microsatellite instability. Patients were followed up for a period of 24 months to monitor any transformation to OSCC. Genetic expression was quantified using real-time PCR, and histopathological confirmation of malignancy was performed. Results: Out of 150 patients, 30 (20%) showed positive expression of p53, 45 (30%) exhibited overexpression of cyclin D1, and 25 (16.7%) displayed microsatellite instability. Among the patients with genetic marker expression, 18 (60%) of the p53-positive cases and 22 (48.9%) of the cyclin D1-positive cases developed OSCC. Additionally, 10 (40%) of those with microsatellite instability experienced malignant transformation. The combined presence of p53 and cyclin D1 overexpression was significantly associated with a higher risk of transformation ( Conclusion: This study highlights the potential role of genetic markers, such as p53, cyclin D1, and microsatellite instability, in predicting the malignant transformation of oral leukoplakia. The findings suggest that the combination of these markers may serve as a valuable tool for early diagnosis and risk stratification in patients with oral leukoplakia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.